Fusion Antibodies Liabilities 2024

Fusion Antibodies Aktienanalyse

What does Fusion Antibodies do?

The company Fusion Antibodies PLC is a biotechnology company specializing in the production of antibodies for medical and scientific research. The company, based in Belfast, Northern Ireland, was founded in 2001 and has been listed on the London Stock Exchange since 2017. Fusion Antibodies' business model is based on the development of customized antibodies for customers in the pharmaceutical, biotech, diagnostics, and academic research sectors. The company offers a wide range of services throughout the entire antibody development process, from antigen design to the production of recombinant antibodies and antibody conjugates. Fusion Antibodies divides its business operations into three main departments: antibody engineering, antibody production, and antibody conjugation. The antibody engineering department is involved in the discovery and optimization of antibodies using advanced technologies such as phage display and hybridoma technologies. In the antibody production department, the desired antibodies are produced through cell culture or recombinant technologies. Finally, in the antibody conjugation department, the antibody is coupled with other molecules such as enzymes, toxins, or fluorescent dyes to generate new therapeutic agents or diagnostic systems. Fusion Antibodies also offers a variety of products that can be either individually configured by customers or purchased as standard products. The portfolio of standard products includes antibodies against known target molecules such as GFP, His-tag, and HA-tag, as well as antibodies tailored to specific applications such as anti-idiotypic antibodies or antibodies for the detection of posttranslational modifications of proteins. In addition, Fusion Antibodies also offers a customized service for the production of antibodies against customer-specific target molecules, tailored to the individual needs of the customer. Fusion Antibodies has numerous customers from the biopharmaceutical and biotechnology industry, as well as from academic research. The company works closely with its customers to meet their specific requirements and offers flexibility and a creative approach through its technology platform in developing solutions for their challenges. The company has a strong R&D department and continuously invests in the development of new technologies and products to maintain and expand its competitiveness. Fusion Antibodies also has partnerships with other companies and institutions in the biotech industry to jointly develop new technologies and products. Overall, Fusion Antibodies is an innovative company specializing in the development of antibodies for use in medical and scientific research. Through its wide range of services, products, and partnerships, the company has solidified its position in the biotech industry and is expected to continue to play an important role in the development of new therapeutic and diagnostic approaches. Fusion Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Fusion Antibodies's Liabilities

Fusion Antibodies's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Fusion Antibodies's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Fusion Antibodies's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Fusion Antibodies's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Fusion Antibodies’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Fusion Antibodies stock

What is the level of liabilities of Fusion Antibodies this year?

Fusion Antibodies has a debt balance of 626,999.97 GBP this year.

What were the liabilities of Fusion Antibodies compared to the previous year?

The liabilities of Fusion Antibodies have increased by -49.07% dropped compared to the previous year.

What are the consequences of high debt for investors of Fusion Antibodies?

High liabilities can pose a risk for investors of Fusion Antibodies, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Fusion Antibodies?

Low liabilities mean that Fusion Antibodies has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Fusion Antibodies affect the company?

An increase in liabilities of Fusion Antibodies can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Fusion Antibodies affect the company?

A decrease in the liabilities of Fusion Antibodies can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Fusion Antibodies?

Some factors that can influence the liabilities of Fusion Antibodies include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Fusion Antibodies so important for investors?

The liabilities of Fusion Antibodies are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Fusion Antibodies take to modify the liabilities?

To change its liabilities, Fusion Antibodies can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Fusion Antibodies pay?

Over the past 12 months, Fusion Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Antibodies is expected to pay a dividend of 0 GBP.

What is the dividend yield of Fusion Antibodies?

The current dividend yield of Fusion Antibodies is .

When does Fusion Antibodies pay dividends?

Fusion Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Antibodies?

Fusion Antibodies paid dividends every year for the past 0 years.

What is the dividend of Fusion Antibodies?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Antibodies located?

Fusion Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Antibodies from 11/4/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did Fusion Antibodies pay the last dividend?

The last dividend was paid out on 11/4/2024.

What was the dividend of Fusion Antibodies in the year 2023?

In the year 2023, Fusion Antibodies distributed 0 GBP as dividends.

In which currency does Fusion Antibodies pay out the dividend?

The dividends of Fusion Antibodies are distributed in GBP.